Novartis AG Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Wed, Feb 3, 2027, after the market closes · estimates and history
Novartis AG Forecast
Novartis AG short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 22.1% a year, a typical one-standard-deviation range is 128.17–136.43 over a week, 123.84–140.76 over a month and 103.01–161.59 over a year. (Signals as of 1 Nov 2026.)
Novartis AG Price Chart
Novartis AG Factors
YoY +81.3%
YoY +28.2%
YoY +48.2%
YoY +32.8%
YoY +33.6%
YoY −32.9%
YoY −44.8%
YoY −53.5%
YoY +25.0%
YoY +77.4%
YoY +81.0%
YoY +0.3%
YoY +2.3%
YoY −29.7%
YoY +79.6%
YoY −28.6%
YoY −8.1%
Novartis AG fundamentals: income statement, balance sheet & cash flow
Novartis AG reported revenue of 57.13bn CHF and net income of 14.65bn CHF in FY2025, the year ended 31 December 2025 — revenue up 10.4% and net income up 22.7% on the prior year. Free cash flow was 18.43bn CHF. These figures are as reported in the filings, not restated: 28 fiscal years and 107 quarters of history, back to December 1998.
| CHF billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 57.13 | 51.72 | 46.66 | 43.46 | 43.97 |
| Cost of revenue | 14.27 | 12.83 | 12.47 | 11.58 | 11.74 |
| Gross profit | 42.86 | 38.90 | 34.19 | 31.88 | 32.24 |
| Research & development | 11.20 | 10.02 | 11.37 | 9.17 | 8.64 |
| Operating income | 17.80 | 14.54 | 9.77 | 7.95 | 10.06 |
| EBITDA | 23.96 | 20.72 | 18.26 | 14.68 | 30.91 |
| Interest expense | 1.24 | 1.01 | 0.92 | 0.86 | 0.90 |
| Pre-tax income | 17.13 | 13.64 | 9.12 | 7.18 | 24.53 |
| Income tax | 2.50 | 1.70 | 0.55 | 1.13 | 1.63 |
| Net income | 14.65 | 11.94 | 14.85 | 6.96 | 24.02 |
Download Novartis AG fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.NOVN.SW&statement=all&freq=a&format=csv&years=10
Figures in CHF, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Novartis AG
Explore MacroFinance macro & markets research and analysis.
Novartis AG Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Novartis AG; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Novartis AG’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Novartis AG (Switzerland)
Novartis AG is a listed security in Switzerland. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Novartis AG
Frequently asked questions
What is Novartis AG?
What is the latest Novartis AG price?
Is Novartis AG in an uptrend?
How volatile is Novartis AG?
What factors affect Novartis AG?
Which trading strategies trade Novartis AG?
How are Novartis AG returns analysed?
Where can I download free Novartis AG historical data?
Free Novartis AG historical data (last 10 years)
Browse or instantly download the last 10 years of Novartis AG daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NOVN.SW&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 127.76 |
| 2026-11-19 | 127.24 |
| 2026-11-18 | 131.48 |
| 2026-11-17 | 133.28 |
| 2026-11-16 | 135.76 |
| 2026-11-13 | 134.06 |
| 2026-11-12 | 134.22 |
| 2026-11-11 | 132.74 |
| 2026-11-10 | 134.48 |
| 2026-11-09 | 133.46 |
About this stock
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.